Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam.

TypePublic
HQMalvern, US
Founded2006
Size (employees)195 (est)
Websiterecropharma.com
Recro Pharma was founded in 2006 and is headquartered in Malvern, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd
Show all (1)
Report incorrect company information

Recro Pharma Financials and Metrics

Recro Pharma Revenue

Recro Pharma's revenue was reported to be $71.83 m in FY, 2017
USD

Revenue (Q2, 2018)

41.3 m

Gross profit (Q2, 2018)

18.7 m

Gross profit margin (Q2, 2018), %

45.3%

Net income (Q2, 2018)

(25.2 m)

EBIT (Q2, 2018)

(26.2 m)

Market capitalization (20-Sep-2018)

154.6 m

Closing stock price (20-Sep-2018)

7.5

Cash (30-Jun-2018)

48.9 m

EV

160 m
Recro Pharma's current market capitalization is $154.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

52 m69.3 m71.8 m

Revenue growth, %

33%

Cost of goods sold

28.1 m37.2 m38.2 m

Gross profit

23.9 m32.2 m33.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

18.7 m16.5 m17.7 m17.3 m17 m18.7 m16.9 m19.5 m41.3 m

Cost of goods sold

9.4 m10 m10.3 m9.5 m5.7 m10.5 m10.4 m10.5 m22.6 m

Gross profit

9.3 m6.5 m7.5 m7.7 m11.2 m8.2 m6.5 m9.1 m18.7 m

Gross profit Margin, %

50%39%42%45%66%44%38%46%45%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

19.7 m19.8 m64.5 m61 m

Accounts Receivable

89.6 k8.6 m10.4 m9.7 m

Inventories

9 m1.1 m9.8 m

Current Assets

20.4 m38.7 m84.8 m87.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

29.9 m27.8 m23.9 m16.6 m15.7 m28.3 m14.9 m14.8 m24.8 m19.5 m8.7 m46.3 m48.9 m

Accounts Receivable

35.8 k86.8 k80.2 k15 m9.6 m12.2 m11.5 m12.4 m12.3 m10.1 m9.8 m11.7 m

Inventories

9.6 m8.6 m7.6 m6.7 m9.8 m7.8 m6.9 m10 m8.1 m

Current Assets

30.2 m28.1 m24.1 m17.3 m42.4 m48.4 m36.2 m35.2 m49 m77.3 m69.8 m79.3 m79 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1 m)3 m(30.2 m)(50.1 m)

Depreciation and Amortization

1.4 k4.1 m5 m4.9 m

Inventories

1.3 m(325 k)(1.1 m)

Accounts Payable

1.1 m2.2 m8.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(5.1 m)(7.9 m)(12.7 m)(4.1 m)(5.5 m)(7.6 m)(6.5 m)(14.4 m)(19.8 m)(8.1 m)(16.9 m)(12.5 m)(25.2 m)

Depreciation and Amortization

1.3 m2.7 m1.3 m2.5 m3.8 m1.2 m2.4 m1.2 m2.5 m

Inventories

345 k1.4 m1.3 m2.3 m(830 k)936 k1.9 m(189 k)1.7 m

Accounts Payable

306.9 k988.5 k1.6 m532.7 k4 m2.7 m2.6 m1.9 m4.5 m(2.4 m)
USDY, 2018

EV/EBIT

-6.1 x

EV/CFO

-6.6 x

Financial Leverage

7.4 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Pharma Revenue Breakdown

Embed Graph

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Report incorrect company information

Recro Pharma News and Updates

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will participate in the following upcoming i…

Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced three poster presentations at PAINWeek 2018, taking place September 4-8, …

Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

Conference Call and Webcast Scheduled for Tuesday, August 7, 2018 at 8:00 a.m. ET Conference Call and Webcast Scheduled for Tuesday, August 7, 2018 at 8:00 a.m. ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - REPH

NEW YORK, June 20, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ:  REPH) and certain of its officers.   The class action, filed in United States District Court, Eastern Distric...
Show more
Report incorrect company information

Recro Pharma Company Life and Culture

Report incorrect company information